Gilead gets Sovaldi patent approval in India despite opposition

Gilead has been granted a patent for its hepatitis C drug Sovaldi (sofosbuvir) in India, despite concerns over the cost of the drug.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia-Pacific

Australia boutique hires experienced life sciences litigator

23 February 2023 New recruit joins from DLA Piper and will head up firm’s litigation team | Previously worked on Pfizer v Samsung Bioepis, Jusand v Rattlejack & Murray Engineering, and Pfizer v Sandoz | Follows prosecutor Chris Vindurampulle who joined in October last year.

Asia-Pacific

Australian court rejects Boehringer opposition bid against MSD unit’s anti-parasitic drug patent

24 May 2022 The Federal Court of Australia has refused an appeal request in a decade-long case brought by Boehringer Ingelheim Animal Health against MSD subsidiary, Intervet International.

Asia-Pacific

Wyeth secures Australian injunction against MSD vaccine

30 November 2020 The Federal Court of Australia has granted Pfizer subsidiary Wyeth’s bid for an injunction against Merck Sharp Dohme in a dispute over vaccine patents.

More features

From migraine drugs to COVID vaccine spats, US lawsuits pile up

Deadline extended: Who are the world’s best in-house counsel?

‘All voices must be heard’: New CIPA president sets out plans for 2026

Insulin pump rivals face off in major trade secrets dispute hearing

Bayer enters COVID-19 vaccine row with three suits against major drugmakers

Arnold & Porter loses another regulatory partner to growing rival

CIPA’s outgoing president: UK rejoining the UPC needs ‘support from business’

Merchant & Gould hires 13 attorneys to open new Boston office

Gilead gets Sovaldi patent approval in India despite opposition

More on this story

Editor's picks

Editor's picks

More features